Linatil

Enalapril Maleate, the active ingredient in Linatil, is an ACE inhibitor presented as an oral tablet for oral use. It is employed to lower high blood pressure and to improve outcomes in patients with heart failure or left ventricular dysfunction following a myocardial infarction.

GNH USA supplies Linatil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory documentation for export to multiple regions. Customers benefit from reliable delivery schedules and dedicated technical support.

Enalapril is an ACE inhibitor used in cardiovascular conditions that involve the renin‑angiotensin‑aldosterone system.

Hypertension: lowers systemic arterial pressure by inhibiting angiotensin‑II formation, leading to vasodilation and reduced peripheral resistance. Heart failure: decreases cardiac workload and improves ventricular function by reducing afterload and neurohormonal activation. Post‑myocardial infarction left ventricular dysfunction: limits adverse cardiac remodeling and lowers the risk of subsequent heart failure events.

Enalapril may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Cough: dry, persistent cough. - Dizziness or light‑headedness. - Headache. - Fatigue. - Hyperkalemia: elevated blood potassium.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway. - Severe hypotension: marked drop in blood pressure. - Renal impairment: worsening kidney function. - Neutropenia or agranulocytosis: low white blood cell count.

When prescribing Enalapril, clinicians should consider several precautionary measures to ensure patient safety.

Blood pressure monitoring: check for hypotension after initiation or dose changes. Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. Serum electrolytes: monitor potassium levels regularly. Caution in diabetes: increased risk of renal dysfunction. History of angioedema: avoid use in patients with prior ACE‑inhibitor–induced angioedema. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Enalapril can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use may increase risk of renal impairment, hyperkalemia, and hypotension. - Lithium: concurrent use can raise lithium concentrations, leading to toxicity. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen, naproxen): may reduce antihypertensive effect and impair renal function. - Other antihypertensives (e.g., beta‑blockers, diuretics): may enhance blood pressure lowering, requiring dose adjustments. - ARBs (angiotensin II receptor blockers): combined therapy increases risk of renal dysfunction and hyperkalemia; monitor labs.